Clinical Trial Update: TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating TACE in combination with bevacizumab for hepatocellular carcinoma beyond the Up-To-Seven criteria (BCLC-B).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• TACE

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma by BCLC Stage | Phase 2 | Status: UNKNOWN